Case presentation 2: Metastatic kidney cancer.
In July 2018, a 65-year-old male Mexican patient with no previous medical history, but with type II diabetes, presented hematuria. A diagnosis of clear cell renal cell carcinoma was diagnosed and was tread with nephrectomy. In December 2018, at routine follow-up, two 4 mm and 5 mm (Fig. 2) lung nodules were detected, and the patient started targeted therapy with Axitinib 5 mg every 12 h and monthly immunotherapy with Pembrolizumab 100 mg/ 4 ml. The patient presented side effects such as constipation, indigestion, tinnitus, extreme fatigue, thrombocytopenia, cough, arthralgia, weight loss, rash and dysgeusia, a medical reason for intermittent discontinuation of treatment. In 2019, the size of one of the pulmonary nodules increased to 9 mm and 12 mm (Fig.3).
In December 2020, the patient decided to discontinue conventional therapy, and started the oral and absorption enema CDS protocol. Additionally, the patient practices a reduced protein diet. The patient manifested no side effects with CDS intake, currently continues the treatment and leads a normal life. As of 2023 the patient is in complete remission, with a fifty-eight-month follow-up.